Overview

Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)

Status:
Not yet recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

An open label study to assess the safety, tolerability, and effects of intranasal Ketamine in combination with rTMS for patients with treatment-resistant major depressive disorder (TRD). Patients will be given a dose of ketamine followed by 6 weeks of rTMS treatment.

Phase:

Phase 4

Details

Lead Sponsor:

University of Cincinnati

Treatments:

Ketamine